. Mechanism of preserved positive lusitropy by cAMP-dependent drugs in heart failure. Am. J. Physiol. Heart Circ. Physiol. 278: H313-H320, 2000.-In tachycardia-induced heart failure (HF), positive lusitropic effects of milrinone or dobutamine were assessed by evaluating the time constant of left ventricular (LV) pressure decay () and Ca 2ϩ -ATPase activity of the sarcoplasmic reticulum (SR). The peak value of the positive first derivative of LV pressure (ϩdP/dt) was less increased, either by dobutamine (2-10 µg · kg Ϫ1 · min Ϫ1 ) or by milrinone (4-20 µg/kg), in HF than in control (P Ͻ 0.05), whereas was shortened to an extent similar to that in control with dobutamine [P ϭ not significant (NS)] and to an even greater extent with milrinone (P Ͻ 0.05). Ca 2ϩ -ATPase activity increased similarly in HF and control with dobutamine (1 µM; ϩ11% in HF vs. ϩ12% in control, P ϭ NS), whereas it increased more with milrinone (1 µM; ϩ19% in HF vs. ϩ11% in control, P Ͻ 0.05). Ca 2ϩ -ATPase activity-cAMP relationships were shifted to the left by milrinone or dobutamine in HF compared with control. Thus, in HF, the sensitivity of Ca 2ϩ -ATPase activity to cAMP was increased on addition of cAMP-dependent inotropic agents, contributing to the preservation of positive lusitropy.
IN HEART FAILURE, the contractile response to ␤-adrenergic stimulation is attenuated through the mechanism by which the basal intracellular cAMP level is decreased, i.e., downregulation of myocardial ␤-adrenoreceptor and increase in inhibitory guanine-nucleotide binding proteins (G i ) (4, 5, 29) . Both ␤-adrenergic agonists and phosphodiesterase (PDE) inhibitors have the capability to increase cAMP levels, leading to an enhancement of cardiac contractility (22) . Although the clinical benefits of positive inotropism by these drugs have been well established in heart failure, the beneficial role of these cAMP-dependent inotropic agents on left ventricular (LV) relaxation in heart failure remained to be elucidated. In this regard, diastolic dysfunction is a major clinical problem in cardiac hypertrophy and/or failure as well as systolic dysfunction, and sometimes cardiac failure can be induced only by diastolic dysfunction even though systolic function is well preserved (3, 9, 10) . Therefore, for the clinical use of these cAMP-dependent drugs, it is important to clarify the difference in positive lusitropic effects between the drugs.
Abnormal regulation of intracellular Ca 2ϩ by the sarcoplasmic reticulum (SR) has been shown to be involved in the mechanism of contractile and relaxation dysfunction in heart failure (30, 32) . Several investigators demonstrated that Ca 2ϩ uptake by SR is decreased in association with the decreased density of Ca 2ϩ -ATPase in cardiac hypertrophy and/or failure (8, 11, 18, 21, 23, 25, 28) . In a previous report (42) , we demonstrated that a low dose of milrinone substantially improved LV relaxation in normal dogs and that this positive lusitropic effect of milrinone was coupled with a direct acceleration of Ca 2ϩ uptake by SR, probably caused by an inhibition of membrane-bound PDE III in SR and hence local elevation of cAMP.
The goal of this study was to evaluate the effects of two different cAMP-dependent drugs, milrinone and dobutamine, on LV relaxation in parallel with the assessment of SR Ca 2ϩ -ATPase activity in tachycardiainduced heart failure. Tachycardia induced by chronic pacing causes well-defined, predictable, and progressive LV dilatation, contractile dysfunction, and neurohormonal activation (2, 7, 27, 33, 41) , and hence this model may more clearly resemble cardiac failure in humans than do previous studies of small-animal models of cardiac hypertrophy and/or failure.
MATERIALS AND METHODS
Heart failure was induced in beagle dogs of either sex by 3 wk of rapid ventricular pacing at a rate of 250 beats/min using an externally programmable miniature pacemaker (Medtronic, Minneapolis, MN). The specific details of the chronic instrumentation were as follows. Beagle dogs (n ϭ 7 for control; n ϭ 7 for rapid ventricular pacing) were sedated with morphine sulfate (15 mg sc) and thiopental sodium (150 mg iv). They were then anesthetized with isoflurane (2%, 1.5 l/min) and a mixture of nitrous oxide and oxygen (2:1), intubated with a cuffed endotracheal tube, and ventilated at a tidal volume of 22 ml/kg and a respiratory rate of 15 breaths/ min. A bipolar pacing lead was fixed to the endocardial rapid
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked ''advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ventricular pacing surface and the distal lead was tunneled to a subcutaneous pocket constructed on the animal's back, and they were connected to a pacemaker (Medtronic). Cefazolin (1 g iv) was administered before and after surgery. The control dogs underwent only a sham operation without pacing.
After 1 wk was allowed for animal recovery, the pacemaker was programmed to 250 beats/min. Dogs were monitored daily for clinical signs and symptoms of heart failure. With the pacing off after 3 wk of rapid ventricular pacing, the dogs were anesthetized after sedation as described above. LV pressure was measured by a 7-Fr micromanometer (Millar) inserted percutaneously via the carotid artery, and twodimensional short-axis echocardiograms were obtained at the level of the head of the papillary muscle. Before insertion, the catheter was calibrated at 37°C with a mercury manometer. Zero shift of the pressure transducer was checked by a simultaneous recording of a fluid-filled transducer (model P23 Db, Gould Statham), in which the zero reference point was taken at the level of the right atrium.
Experimental protocol. After control recording, a stepwise intravenous infusion of dobutamine (2-10 µg · kg Ϫ1 · min Ϫ1 ) was started. Five to ten minutes were allowed to obtain a steady state at each dose, and hemodynamic measurements were made at the end of each infusion rate. After the dobutamine infusion, pre-milrinone baseline hemodynamic values were established by waiting at least 3 h, by which time all measurements returned almost to the initial baseline values. Milrinone was then intravenously administered by a stepwise cumulative infusion of 4-20 µg/kg with repeat hemodynamic measurements. The order of drug administration was not randomized because of the long duration of milrinone's hemodynamic effects.
All data were recorded at the end of an expiration on a multichannel recorder (Electronics for Medicine VR12) digitized at intervals of 2 ms with an on-line analog-to-digital converter. To obtain data for analysis, we used the average of 10 consecutive cardiac cycles. End diastole was defined by the peak of the R wave on the electrocardiogram. The time of the peak value of the negative first derivative of LV pressure (ϪdP/dt), obtained from the digital data of the dP/dt signal, was used to estimate end systole. The time constant of LV pressure decay () was calculated as the negative inverse slope of the natural log of pressure vs. time relationship, with the assumption of a pressure asymptote of 0 mmHg and with use of data from peak ϪdP/dt to 10 mmHg above the enddiastolic pressure (40) .
The care of the animals and the protocols used were in accordance with guidelines laid down by the Animal Ethics Committee of Yamaguchi University School of Medicine.
Preparation of LV crude homogenate. The homogenate was prepared as described previously (12) . LV were homogenized in a solution containing 30 mM Tris-malate, 0.3 M sucrose, 5 mg/l leupeptin, and 0.1 mM phenylmethylsulfonyl fluoride, at pH 7.0. The homogenate was centrifuged at 5,500 g for 10 min, and the resultant supernatant was filtered through four layers of cheesecloth.
Ca 2ϩ -ATPase activity and cAMP assays. Ca 2ϩ -ATPase activity in LV crude homogenate (control, n ϭ 6 preparations; heart failure, n ϭ 6 preparations) was obtained by measuring the amount of P i released during the reaction after ATP was added. The assay mixture in a total assay volume of 500 µl contained 150 mM KCl, 20 mM MES (pH 6.8), 0.3 mM MgCl 2 , 10 mM NaN 3 , 10 mM NaF, 6 µM ionophore A-23187, 0.32 mM CaCl 2 , 0.5 mM EGTA (free [Ca 2ϩ ] ϭ 1 µM), and crude homogenate (0.125 mg). To start the reaction, 1.0 mM ATP was added to the above priming solution in the presence or absence of dobutamine (0.1-10 µM) or milrinone (0.1-10 µM). The amount of P i reacted was calculated by converting nanometers (absorbance of 0.1% malachite green) to nanomoles by means of a standard linear line (13, 24) .
The cAMP content in LV crude homogenate (control, n ϭ 6 preparations; heart failure, n ϭ 6 preparations) was determined with an enzyme immunoassay kit (Biotrak, cAMP enzyme immunoassay system, Amersham International) according to the kit instructions.
Statistics. Unpaired t-test was used to compare the hemodynamic data between control and heart failure. Changes within the same group were analyzed by one-way ANOVA for repeated measures and subsequent Fisher's protected least significant difference (PLSD). Differences between two groups were analyzed by two-way ANOVA and subsequent Fisher's PLSD. Data are presented as means Ϯ SE. Statistical significance was defined by P Ͻ 0.05.
RESULTS

Hemodynamics in the basal condition.
Hemodynamics are summarized in Table 1 . After chronic rapid ventricular pacing, heart rate, LV end-diastolic pressure, and LV internal diameters were all increased, compared with control. As for the parameters of LV systolic function, the peak ϩdP/dt of LV pressure, cardiac output, and fractional shortening were significantly decreased. As for the parameters of LV diastolic function, the time constant of LV pressure decay during isovolumic relaxation period () was prolonged after rapid right ventricular pacing.
Hemodynamic changes after administration of milrinone or dobutamine. Hemodynamics before and after infusion of milrinone or dobutamine are summarized in Table 2 . After the administration of dobutamine (2-10 µg·kg Ϫ1 · min Ϫ1 ), LV peak pressure was slightly increased in control conditions and unchanged in heart failure. LV end-diastolic pressure tended to increase in control and was unchanged in heart failure. Peak ϩdP/dt increased and was shortened in both groups. As shown in Fig. 1 , peak ϩdP/dt increased to a lesser extent in heart failure than in control, whereas was shortened to a similar extent as in control. Values are means Ϯ SE; n, no. of dogs. HR, heart rate; LVPSP, left ventricular (LV) peak systolic pressure; LVEDP, LV end-diastolic pressure; peak ϩdP/dt, peak value of first derivative of LV pressure; , time constant of LV pressure decay during isovolumic relaxation period; CO, cardiac output; SV, stroke volume; LVEDD, LV enddiastolic diameter; LVESD, LV end-systolic diameter; %FS, % fractional shortening [(LVEDD Ϫ LVESD)/LVEDD ϫ 100]. * P Ͻ 0.05 vs. control.
After the administration of milrinone, heart rate was slightly increased in control and unchanged in heart failure. LV peak pressure was unchanged in either control or heart failure. LV end-diastolic pressure decreased in both groups. Peak ϩdP/dt increased and was shortened in both groups. As shown in Fig. 2 , peak ϩdP/dt increased to a lesser extent in heart failure than in control, whereas was shortened much more than in control by low doses of milrinone (4-12 µg/kg).
Ca 2ϩ -ATPase activity and cAMP level in presence of milrinone or dobutamine. As summarized in Table 3 , both cAMP and Ca 2ϩ -ATPase activity in crude homogenate were significantly decreased in heart failure compared with control. After the addition of dobutamine, the cAMP increased in a dose-dependent manner to a lesser extent in heart failure than in control (Fig.  3A) . Ca 2ϩ -ATPase activity was increased in a dosedependent manner in both groups (Fig. 3B) . There was no significant difference in the percent increase of Ca 2ϩ -ATPase activity from baseline between control and heart failure. On the other hand, after milrinone was added, cAMP increased similarly in both groups (Fig. 4A) , whereas Ca 2ϩ -ATPase activity was increased to a greater extent in heart failure than in control at low doses of milrinone (Fig. 4B) . Figure 5 shows the relationship between the percent change of Ca 2ϩ -ATPase activity and the percent change of cAMP in the presence of dobutamine (Fig. 5A) or milrinone (Fig. 5B) . In the presence of either dobutamine or milrinone, Ca 2ϩ -ATPase activity (%)-cAMP (%) relationship curves were shifted to the left in heart failure compared with control, indicating higher sensitivity of Ca 2ϩ -ATPase activity to cAMP in heart failure. Compared with dobutamine, low doses of milrinone exerted a substantial increase in Ca 2ϩ -ATPase activity in heart failure, at a given increase in cAMP.
In the presence of 1 µM thapsigargin (SR Ca 2ϩ -ATPase inhibitor), Ca 2ϩ -ATPase activity was decreased by 17.7 Ϯ 3.1% in normal homogenate and by 19.6 Ϯ 1.8% in heart failure homogenate. There was no significant difference in the percentage of the thapsigarginsensitive portion of Ca 2ϩ -ATPase activity between normal and heart failure. Figure 6 shows the effect of dobutamine or milrinone on the thapsigargin-insensitive portion of Ca 2ϩ -ATPase activity in normal (Fig. 6A ) and heart failure (Fig. 6B) . There was no significant change in the thapsigargininsensitive portion of Ca 2ϩ -ATPase activity at various doses of dobutamine or milrinone. 
DISCUSSION
The major findings of this study are as follows. First, in heart failure, the positive lusitropic effect of either milrinone or dobutamine was well preserved in association with the increased sensitivity of SR Ca 2ϩ -ATPase activity to cAMP. Second, in particular, the positive lusitropic effect of low doses of milrinone was more prominent in heart failure than in normal conditions, associated with a marked stimulation of SR Ca 2ϩ -ATPase activity.
Preservation of positive lusitropy in heart failure. Much evidence has accumulated that in heart failure, the positive inotropic response to catecholamine is significantly decreased, whereas positive lusitropy is well preserved (26, 31) . The reduction of the positive inotropic action of dobutamine after heart failure might be caused by high production of NO (17) . Keaney et al. (16) found that intracoronary infusion of the nitric oxide synthase inhibitor N G -nitro-L-arginine methyl ester increased peak ϮdP/dt in response to intracoronary infusions of either dobutamine or isoproterenol in the in situ canine heart. Consistent with these previous reports, we found that both dobutamine and milrinone caused less increase in LV contractility in heart failure than under normal conditions, whereas lusitropic responses to both drugs were well preserved. Although the underlying mechanism is still unclear, in heart failure the lusitropic response might be coupled more efficiently to cAMP than the inotropic responses on stimulation of either dobutamine or milrinone. Sensitivity of the lusitropic cascade (i.e., phosphorylation of phospholamban, interaction of phospholamban to Ca 2ϩ -ATPase, etc.) to cAMP may be increased in heart failure. As a matter of fact, we found that Ca 2ϩ -ATPase Fig. 1 . Effect of dobutamine on percent change in peak value of positive 1st derivative of left ventricular (LV) pressure (ϩdP/dt; A) and in time constant of LV pressure decay during isovolumic relaxation period (; B) from baseline. Values are means Ϯ SE. * P Ͻ 0.05 vs. baseline, † P Ͻ 0.05 vs. control. In heart failure, peak ϩdP/dt increased less than in control after infusion of dobutamine, whereas was shortened to a similar extent as in control. Fig. 2 . Effect of milrinone on percent change in ϩdP/dt (A) and in (B) from baseline. Values are means Ϯ SE. * P Ͻ 0.05 vs. baseline. † P Ͻ 0.05 vs. control. In heart failure, peak ϩdP/dt increased less than in control after the infusion of low doses of milrinone, whereas was shortened much more than control. activity in heart failure was more enhanced at a given increase in cAMP either by dobutamine or by milrinone than under normal conditions (Fig. 5) . As another possibility, the recently proposed functional compartmentation of cAMP (1, 6) might partly explain the discordance in inotropic or lusitropic action to cAMPdependent drugs in heart failure. In heart failure, the cAMP produced either by dobutamine or by milrinone may be better compartmentalized for the elevation of local cAMP in lusitropic response than in inotropic response.
Mechanisms by which milrinone exerts predominant acceleration of LV relaxation in heart failure. Using the model of pacing-induced heart failure, two recent studies have shown that 1) gene expression and activity of PDE III are reduced in SR (37) and 2) cAMP and PDE levels are preferentially reduced in the subendocardium (34) . These findings may account in part for the reduced positive inotropic effect of milrinone and also the predominant positive lusitropy and activation of Ca 2ϩ -ATPase by low doses of milrinone.
Recently, a particulate, high-affinity type IV cAMP-PDE activity was shown to exist in cardiac SR (14) . In this regard, much evidence has accumulated that certain cardiotonic agents (milrinone, imazodan, and amrinone) inhibit this SR membrane-bound ''low K m '' or ''cGMP-inhibited'' PDE type IV isozyme (35, 38, 39) and exert their contractile effects through subtle alterations in the metabolism of cAMP (15, 19) . With regard to this, functional compartmentation of cAMP and protein kinases was previously proposed for cardiac muscle (1, 6) , and intracellular Ca 2ϩ mobilization might be affected by cAMP located in the particulate compartment of canine cardiac myocytes (6) . Because milrinone, at submicromolar concentrations, inhibits specifically SR membrane-bound PDE III activity (19) , the acceleration of SR Ca 2ϩ -ATPase activity by low doses of milrinone might be caused by an inhibition of membrane-bound PDE III in SR, followed by a local elevation of cAMP, not the global cytosolic elevation of cAMP. Indeed, we previously demonstrated (42) that a low dose of milrinone significantly enhanced LV relaxation Fig. 3 . Effect of dobutamine on cAMP level (A) and Ca 2ϩ -ATPase activity (B) in LV crude homogenates. Values are means Ϯ SE. * P Յ 0.05 vs. baseline; † P Յ 0.05 vs. control. Dobutamine increased cAMP to a lesser extent in heart failure than in control. Ca 2ϩ -ATPase activity was increased in a dose-dependent manner, and there was no significant difference in response between control and heart failure. in association with the substantial increase in the rate of Ca 2ϩ uptake by cardiac SR. This effect of milrinone might also explain why, in this study using LV homogenate, milrinone exerted more increase in the Ca 2ϩ -ATPase activity in heart failure than dobutamine at a given increase in cAMP (Fig. 5) .
Limitations. Milrinone exerts a vasodilating effect as well as positive inotropic and lusitropic effects. Therefore, afterload reduction by this drug may possibly induce acceleration of LV relaxation. With regard to this, when LV pressure was increased by ϳ25% (mean 30 mmHg) by addition of phenylephrine together with milrinone, was not significantly influenced in normal dogs (unpublished data). Furthermore, in the present study, the low dose of milrinone (4 µg/ml) did not change peak LV pressure and LV end-diastolic pressure, whereas was shortened by 16% in heart failure. Therefore, the PDE-inhibitory effect of milrinone might be predominantly involved in the positive lusitropic effect, particularly at a low dose. At higher doses of milrinone, the mixed effects of PDE III inhibition and vasodilatation may play important roles in the improvement of LV relaxation.
In the present study, we measured whole Ca 2ϩ -ATPase activities in myocardium. However, the SR Ca 2ϩ -ATPase activity alone comprises ϳ25% of the total muscle homogenate activity, and ϳ75% of total Ca 2ϩ -ATPase activity in muscle homogenate is provided by intracellular organs other than SR, i.e., Ca 2ϩ -Mg 2ϩ -ATPase of the plasmalemma and myofibrils (36) . Therefore, we should address the reaction of these other Ca 2ϩ -ATPase activities to milrinone or dobutamine in this study. As shown in Fig. 6 , thapsigargininsensitive Ca 2ϩ -ATPase activity, which comprises ϳ80% of total Ca 2ϩ -ATPase activity, was influenced by neither dobutamine nor milrinone. Only the thapsigargin-sensitive portion of Ca 2ϩ -ATPase activity was changed by these drugs, indicating that these positive inotropic agents indeed affect SR Ca 2ϩ -ATPase activity.
In the present study, the degree of heart failure appears moderate (heart rate ϳ100 beats/min, no change in LV systolic pressure, LV end-diastolic pressure Ͻ25 mmHg) compared with the hemodynamic values reported in the literature (20, 26, 37) . In severe heart failure, the cytosolic level of cAMP and the protein expression of Ca 2ϩ -ATPase might substantially decrease, and hence the positive lusitropic responses to cAMP-dependent drugs may deteriorate no matter how SR Ca 2ϩ -ATPase activity is hypersensitized to cAMP. Also, it is likely that the sensitivity of SR Ca 2ϩ -ATPase activity to cAMP may change depending on the severity of heart failure. Clearly, more work is needed.
In conclusion, 1) positive lusitropic effects by cAMPdependent drugs were well preserved, probably because of the higher sensitivity of SR Ca 2ϩ -ATPase activity to cAMP in heart failure, and 2) a low dose of milrinone substantially improved LV relaxation in association with stimulation of SR Ca 2ϩ -ATPase activity in heart failure much more than under normal conditions.
